tbuckley/cabot-search huggingface dataset:
Feasibility of treatment of relapsed NSCLC with accelerated pemetrexed given every 2 weeks
Authors: C. E. Emmanouilides, E. Sapountzi, D. Diamandidis
Journal: Journal of Clinical Oncology (2008)

19106 Background: Pemetrexed has been approved for the treatment of relapsed NSCLC and is characterized by excellent tolerance when appropriate vitamin supplementation is provided. Based on the relatively lack of myelosuppression, the current exploratory study investigates the feasibility of dosing frequency of 2 weeks Methods: Patients with relapsed NSCLC otherwise eligible to receive commercially available pemetrexed were enrolled. Patients were required to have a WBC > 2500/ul and platelets > 100000/ul and a ECOG status 0–3. Standard B12 supplementation as well as folic acid 2.5 mg daily were provided. Pemetrexed was dosed at 500 mg/m2 every 2 weeks, until disease progression. Response was assessed after the third administration. Results: Sixteen patients have been treated with the following characteristics: median age: 66, male:13, female:3, adenoca: 14; ECOG PS: 0: 1 pt, 1:4 pts, 2: 8 pts, 3: 3 pts; 8 patients received pemetrexed as 2nd line treatment, whereas 7 as 3rd and 1 as 4th. The median number of administrations were 4. Grade 3–4 neutropenia was noted in one patient and grade 3–4 thrombocytopenia in another. Dose delay was required in 2 instances. No prophylactic WBC growth factor was used. One patient required blood transfusion, whereas erythropoietin supplementation was provided as needed. Other significant toxicity included asthenia grade 3 (4 patients). Stable disease was noted in 10 patents and progression in 6, with a median TTP of 9 weeks. Conclusions: This preliminary study suggests that administration of standard dose pemetrexed every 2 weeks is feasible and well tolerated even in our particularly adverse group of patients. Larger studies are needed to further assess the clinical usefulness of such an accelerated regimen. No significant financial relationships to disclose.
Abstract 3785: Red Wine Consumption Increases Circulating Endothelial Progenitor Cells and Improves Endothelial Function in Obese Type II Diabetics
Authors: Catherine L Seck, Jochen Mueller-Ehmsen, Gerhard Kreuter, Karl-Heinz Hauser, Daniela Braun, Karin Moog, Christoph Scheid, Thorsten Schneider, Markus Flesch
Journal: Circulation (2007)

Objective: Cardiovascular risk factors are associated with decreased levels of circulating progenitor cells (CPC). The aim of this study was to determine whether the moderate consumption of red wine leads to an increase of CPCs. Methods: CD34 positive and CD133/CD34 as well as CD117/CD34 double positive cells were measured by FACS analysis in peripheral blood of 15 obese patients suffering from type II diabetes with stable oral drug treatment (67.3 ± 2.3 years, BMI 32.3 ± 0.5 kg/ m 2 ) prior to and after a six week period of drinking two units (300 ml) of red wine (Lemberger Classic, Württemberg, Germany). The drinking period was anticipated by a four week fasting period, in which no alcohol consumption was allowed at all. In addition, brachial artery flow mediated dilatation was determined prior to and after the drinking period. Results: The six week drinking period had no effect on BMI, systolic and diastolic blood pressure, blood glucose levels, HbA1c-values and liver enzymes. There was a non-significant drop in LDL cholesterol, but no change in HDL cholesterol. Concerning CPCs, the following alterations were observed: CD34+ cells increased from 171 ± 22 to 354 ± 28 per million leucocytes. Within the CD34+ cells, the percentage of CD133+ cells increased from 30.8 ± 5.7 % to 53.1 ± 3.3 %, and the percentage of CD117+ cells increased from 38.1 ± 5.8 % to 57.5 ± 4.6 % (p&lt;0.05 for all parameters). Brachial artery flow mediated dilatation increased from 5.57 ± 0.74 % to 11.13 ± 1.34 % (p&lt;0.05) in response to six weeks of red wine consumption. Nitroglycerin mediated brachial artery dilatation increased from 7.45 ± 1.09 % to 11.31 ± 1.09 % (p&lt;0.05). Conclusion: In obese patients suffering from type II diabetes, moderate consumption of red wine leads to a significant improvement of circulating progenitor cell count and endothelial function. No adverse effects of wine consumption on metabolic and cardiovascular parameters were observed.
PARENTERAL LIVER THERAPY IN PERNICIOUS ANEMIA: OBSERVATIONS COVERING TWO YEARS OF CONTINUED USE
Authors: Joseph E. Connery, Leonard J. Goldwater
Journal: Annals of Internal Medicine (1934)

Article1 March 1934PARENTERAL LIVER THERAPY IN PERNICIOUS ANEMIA: OBSERVATIONS COVERING TWO YEARS OF CONTINUED USEJOSEPH E. CONNERY, M.D., LEONARD J. GOLDWATER, M.D.JOSEPH E. CONNERY, M.D.Search for more papers by this author, LEONARD J. GOLDWATER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-7-9-1117 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe literature on the parenteral use of liver extract in the treatment of pernicious anemia was extensively reviewed by Conner1in 1932 and subsequently by others. In the main, except for the recent contributions of Murphy2and of Isaacs,3the reports which have so far appeared in the literature have to do with the parenteral use of liver extract over relatively short periods of time. In most instances the observations reported cover the effects of this form of treatment during the period of exacerbation, and therefore deal with parenteral liver therapy as an agent in the induction of remissions. It...Bibliography1. CONNER HM: Injection of liver extract in the treatment of pernicious anemia, Jr. Am. Med. Assoc., 1932, xcix, 614-620. CrossrefGoogle Scholar2. MURPHY WP: Maintenance of normal blood in pernicious anemia by means of intramuscular injections of a solution of liver extract, Am. Jr. Med. Sci., 1933, clxxxvi, 271-277. CrossrefGoogle Scholar3. ISAACSSTURGESGOLDHAMERBETHELL RCCSMFH: Use of liver extract intravenously in the treatment of pernicious anemia, Jr. Am. Med. Assoc., 1933, c, 629-633. CrossrefGoogle Scholar4. COHNMINOTFULTONULRICHSSARGENTWEAREMURPHY EJGRJFHFFCJHWP: The nature of the material in liver effective in pernicious anemia, Jr. Biol. Chem., 1927, lxxiv, p. lxix-lxxii. Google Scholar5. Solution liver extract parenteral, N. N. R., made by the Lederle Laboratories, Inc., New York. Google Scholar6. CONNERYGOLDWATER JELJ: Parenteral use of liver extract in treatment of pernicious anemia, Jr. Am. Med. Assoc., 1932, xcviii, 1060-1067. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication October 19, 1933.From the Department of Medicine, University and Bellevue Hospital Medical College, New York University, and the Third (New York University) Medical Division of Bellevue Hospital.†Prepared by the Lederle Laboratories, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDauerbehandlung der Perniziösen Anämie mit „Pernaemyl Forte“ 1 March 1934Volume 7, Issue 9Page: 1117-1121KeywordsHospital medicineLiverPernicious anemia Issue Published: 1 March 1934 PDF downloadLoading ...
Cortical and Papillary Micropuncture Examination of Chloride Transport in Segments of the Rat Kidney during Inhibition of Prostaglandin Production
Authors: Eiji Higashihara, John B. Stokes, Juha P. Kokko, William B. Campbell, Thomas D. Dubose
Journal: Journal of Clinical Investigation (1979)

Prostaglandins have been postulated to participate in the regulation of salt excretion during acute volume expansion. The present papillary and cortical micropuncture studies were designed to examine the effect of prostaglandin synthesis inhibitors on segmental chloride transport during hydropenia (with and without meclofenamate) and 10% volume expansion (with and without both meclofenamate and indomethacin). Both inhibitors significantly decreased the urinary excretion rate of prostaglandins E(2) and F(2alpha). Clearance studies on the intact right kidney demonstrated no effect of either agent on glomerular filtration rate, but a significant reduction in chloride excretion during hydropenia and volume expansion was observed. To assess the specific site(s) of enhanced chloride reabsorption, absolute and fractional chloride delivery was measured in the late proximal tubule, thin descending limb of Henle, and the early and late distal tubules. In addition, the fraction of filtered chloride remaining at the base and tip of the papillary collecting duct was compared to that fraction remaining at the superficial late distal tubule. During hydropenia, meclofenamate had no effect on fractional chloride delivery out of the superficial late distal tubule or the juxtamedullary thin descending limb of Henle, but significantly reduced the fraction of chloride delivered to the base of the papillary collecting duct. During volume expansion, neither meclofenamate nor indomethacin had an effect on absolute chloride delivery out of the proximal tubule or the thin descending limb of Henle. However, absolute chloride delivery to the early distal tubule was significantly reduced, and was associated with a decrease in fractional chloride reabsorption in this segment. Furthermore, the fraction of chloride delivered to the base of the collecting duct was significantly reduced. Fractional reabsorption along the terminal 1 mm of the collecting duct was not altered by either meclofenamate or indomethacin. These results suggest that inhibitors of prostaglandin synthesis result in an increase in chloride reabsorption in the superficial loop of Henle, and in segments between the superficial late distal tubule and the base of the collecting duct. The results are consistent with the view that prostaglandins inhibit chloride transport in the thick ascending limb of Henle, and/or the cortical and outer medullary collecting tubule.
Reduction in Ephedra Poisonings after FDA Ban
Authors: Michele Zell-Kanter, Meghan A Quigley, Jerrold B Leikin
Journal: New England Journal of Medicine (2015)

The findings of Lagler et al. that current consent templates are written at an education level that exceeds that of the general population are consistent with the findings of others who have evaluated consent forms and templates. 1These data suggest that the institutions where research is conducted, the research teams that write consent forms, or the oversight committees that review them (or all of the above) are not sufficiently focused on the goal of facilitating understanding among potential research participants.This seems true, as consent forms continue to increase in length, complexity, and the incorporation of legal language, thus jeopardizing understanding despite recognition of the need to improve consent forms. 2 I agree that substantial efforts are needed to improve consentform readability and understandability, and those efforts should include attention to the research teams, review groups, and research institutions that shape the consent forms.
Authors' reply to Lin and colleagues
Authors: S. P. Cohen, Y. Vorobeychik
Journal: BMJ (2015)

Lin and colleagues commented that because the differences between treatments were small we were unjustified in recommending one treatment over another.1 2 In our conclusions we stated that it was reasonable to proceed with pharmacotherapy first, given the small differences seen. If physical therapy and surgery—which is associated with much higher costs and risks than physical therapy—were shown to be equivalent, would they still state …
Abstract 15865: Diastolic Pulmonary Artery Pressure to Pulmonary Capillary Wedge Pressure Gradient (DPG) in Over 5700 Patients With an Elevated Transpulmonary Gradient Does Not Predict Survival After Cardiac Transplantation
Authors: Ryan J Tedford, Claude A Beaty, Stephen C Mathai, Todd Kolb, Rachel Damico, Paul M Hassoun, David A Kass, Ashish S Shah
Journal: Circulation (2013)

Background: The transpulmonary gradient (TPG) has been commonly used to differentiate those patients with true pulmonary vascular disease from those with more passive pulmonary hypertension (PH). H...
A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b
Authors: Hongyan Wang, Ramasamy Santhanam, Zhiliang Xie, Xiaomeng Huang, Ming Chiu, Mitch A. Phelps, Alison R Walker, Michael A. Caligiuri, Ramiro Garzon, James Lee, Natarajan Muthusamy, Kenneth K. Chan, Guido Marcucci
Journal: Blood (2013)
Abstract 3837: Complete Revascularization to the Pedal Arch Improves the Limb Salvage Rate in Patients with Critical Limb Ischemia
Authors: hirokuni akahori, Shinsuke Nanto, Osamu Iida, Masaaki Uematsu, Takakazu Morozumi, Jyun-ichi Kotani, Tetsuya Watanabe, Masaaki Awata, Toshinari Onishi, Fusako Sera, Hitoshi Minamiguchi, Masamichi Yano, Hiroki Yasui, Seiki Nagata
Journal: Circulation (2006)
Abstract 4952: Differential Expression in the Determinants of Extracellular Matrix Remodeling in Pediatric and Adult Dilated Cardiomyopathy
Authors: Tain-Yen Hsia, Jeremy M Ringewald, Robert E Stroud, Michael C Graves, Scott M Bradley, Francis G Spinale
Journal: Circulation (2008)

Ventricular phenotype of idiopathic dilated cardiomyopathy (DCM) can appear similar in pediatric and adult patients, but a more aggressive clinical course often occurs with pediatric DCM. A structural underpinning of DCM is extracellular matrix changes, which are determined by a balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs). This study tests the hypothesis that different MMP/TIMP profiles occur in pediatric and adult DCM patients. Left ventricular samples were taken from pediatric (age 12±4 yr; n=5) and adult (age 63±3 yr; n=11) patients during heart transplantation for DCM. Myocardial levels were quantified for all MMP classes: gelatinases (MMP-2, -9), collagenases (MMP-8, -13), lysins (MMP-7), membrane-type (MT1-MMP), and for all 4 known TIMPs. Patients with structural or ischemic etiologies of DCM were excluded. Compared to adults, MMP-8 levels increased by over 350% (Figure ), and MMP-7 and MT1-MMP levels (75±9% and 76±9%, respectively; p&lt;0.05) were lower in pediatric patients. In contrast, pediatric TIMP-1 levels were reduced by over 50% (Figure). Pediatric DCM patients manifest a robust increase in MMP-8, which degrades all components of the extracellular matrix, and a decrease in TIMP-1, which inhibits MMP-8. This heightened MMP-8/TIMP-1 ratio would favor aggressive matrix remodeling in pediatric DCM. Since MMP-8 is primarily expressed by macrophage cell lineage, a unique proteolytic program may exist in pediatric DCM. These distinct differences in determinants of myocardial matrix structure and function likely contribute to the more progressive nature of DCM in children.
THE INTERNIST, PAST, PRESENT AND FUTURE
Authors: W W PALMER
Journal: Annals of Internal Medicine (1949)

Article1 July 1949THE INTERNIST, PAST, PRESENT AND FUTUREWALTER W. PALMER, F.A.C.P.WALTER W. PALMER, F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-31-1-1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is a pleasure to welcome the newly elected Fellows and Associates on this occasion. I am confident that you will enjoy and profit by the privileges and associations which come to you as members of the American College of Physicians.In keeping with tradition, the retiring President is expected to address the Convocation on some phase of medicine which may be of interest or importance to the welfare of the College. Several of my distinguished predecessors on these occasions have presented their ideas of the characteristics, abilities, qualities and responsibilities of the internist. This evening I propose to direct... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Presidential Address, Annual Convocation, Thirtieth Annual Session, American College of Physicians, New York, N. Y., March 30, 1949. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1949Volume 31, Issue 1Page: 1-6KeywordsForecasting ePublished: 1 December 2008 Issue Published: 1 July 1949 Copyright & PermissionsCopyright, 1949, by The American College of PhysiciansPDF downloadLoading ...
Smoking and Lung Cancer: Recent Evidence and a Discussion of Some Questions
Authors: J CORNFIELD, W HAENSZEL, E C HAMMOND, A M LILIENFELD, M B SHIMKIN, E L WYNDER
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article Smoking and Lung Cancer: Recent Evidence and a Discussion of Some Questions Get access Jerome Cornfield, Jerome Cornfield Search for other works by this author on: Oxford Academic PubMed Google Scholar William Haenszel, William Haenszel Search for other works by this author on: Oxford Academic PubMed Google Scholar E. Cuyler Hammond, E. Cuyler Hammond Search for other works by this author on: Oxford Academic PubMed Google Scholar Abraham M. Lilienfeld, Abraham M. Lilienfeld Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin, Michael B. Shimkin Search for other works by this author on: Oxford Academic PubMed Google Scholar Ernst L. Wynder Ernst L. Wynder Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 22, Issue 1, January 1959, Pages 173–203, https://doi.org/10.1093/jnci/22.1.173 Published: 01 January 1959 Article history Received: 15 October 1958 Published: 01 January 1959
Abstract 339: Endogenous Muscle Atrophy F-box is a Positive Mediator of Cardiac Hypertrophy and Dysfunction in Response to Pressure Overload
Authors: Soichiro Usui, Chull Hong, Shumin Gao, Junichi Sadoshima
Journal: Circulation (2007)

Muscle atrophy F-box (MAFbx, Atrogin-1) is an E3 ubiquitin ligase which plays a critical role in mediating skeletal muscle atrophy. It has been shown that cardiac specific expression of MAFbx inhibits pressure overload-induced cardiac hypertrophy, suggesting that MAFbx negatively regulates cardiac mass when overexpressed. To elucidate the role of endogenous MAFbx in regulating cardiac mass, we applied transverse aortic constriction (TAC) to MAFbx −/− and wild type (WT) mice. Pressure gradients in both groups were comparable (MAFbx −/− 90.4 mmHg vs WT 79.3 mmHg). In WT mice, protein expression of MAFbx in the heart was significantly increased (3.5 fold) after 2 weeks of TAC. Unexpectedly, left ventricular weight/body weight (LVW/BW) was significantly smaller in MAFbx −/− than in WT mice (4.49 vs 5.58, p &lt; 0.01). The echocardiographically determined LV posterior wall thickness (1.00 vs 1.13 mm, p &lt; 0.05) and LV mass index (151 vs 193, p &lt; 0.05) after TAC were significantly smaller in MAFbx −/− than in WT mice, consistent with the notion that MAFbx −/− mice develop less hypertrophy in response to TAC. Lung weight/BW after TAC was significantly increased compared with the sham operated group in WT (10.1 vs 5.1, p &lt; 0.01) but not in MAFbx −/− mice (6.0 vs 4.9, NS), suggesting that LV dysfunction after TAC was inhibited in MAFbx −/− mice. Furthermore, picric acid-Sirius red staining revealed that there was significantly less interstitial fibrosis after TAC in MAFbx −/− than in WT mice. These results suggest that MAFbx is up-regulated in response to pressure overload, and that the absence of endogenous MAFbx decreases hypertrophy and interstitial fibrosis and maintains cardiac function. In conclusion, distinct from its essential role in skeletal muscle atrophy, and also in direct contrast to the results seen with mice overexpressing MAFbx, endogenous MAFbx in the heart promotes cardiac hypertrophy and dysfunction during pressure overload.
Abstract 630: Continuous Reduction of N-Terminal Pro-Brain Natriuretic Peptide Levels after Successful Catheter Ablation in Patients with Paroxysmal or Short Persistent Atrial Fibrillation
Authors: Simon Hoenig, Robert Hofmann, Clemens Steinwender, Alexander Kypta, Franz Leisch
Journal: Circulation (2008)

It has been reported previously that elevated N-terminal pro-brain natriuretic peptide levels (BNP) decrease in patients with atrial fibrillation (AF) within one month of pulmonary vein isolation (PVI). The purpose of the study was to examine the development of BNP levels after successful PVI. In 71 patients (mean age of 62 ± 8 years) undergoing successful PVI for drug-resistant highly symptomatic paroxysmal or shortly persistent AF, BNP levels were analysed the day before, 30 days after, three months after and one year after the procedure, respectively. Based on a personal log of duration and frequency of symptoms and repetitive 24h-ECG recordings, patients were divided into two groups: 36 patients had clinical success, and 16 patients had clinical failure. Clinical demographic and procedural data were similar in both groups. Of note, all patients had lone AF without any clinical signs of congestive heart failure. Baseline BNP levels were similar in both groups (387± 550 pg/ml vs. 492 ± 513 pg/ml, p=0.6). After 30 days, patients who had a clinical successful procedure showed a significant decrease of BNP levels compared to those patients with clinical failure (315 ± 430 pg/ml vs. 754 ± 888 pg/ml, p=0.02). After three months, a further reduction of BNP levels could be observed in clinical successful treated patients compared to patients with clinical failure, in whom no significant change compared to baseline could be detected (214 ± 213 pg/ml vs. 673 ± 907 pg/ml, p=0.01). After one year of successful PVI a repeated reduction of BNP in patients with clinical success could be observed (173 ± 198 pg/ml vs. 448 ± 628 pg/ml, p=ns.), but due to the small sample size the difference did not reach statistic significance. Similar to previous observations, BNP levels after successful PVI decreased only in patients with clinical success during follow-up. However, our study revealed a long-term effect showing a further decrease after one year whereas BNP levels showed even a further increase during the first three months in patients without clinical success. This observation points to an underestimated impact of AF concerning congestive heart failure even in patients without regarding symptoms.